https://peptidepolicywatch.com/2026/10/30/why-doctors-cant-prescribe-or-get-peptides-covered/Peptide Policy Watchen2026-10-30Why doctors can't simply prescribe most peptides, or get insurance to pay for them https://peptidepolicywatch.com/2026/10/30/next-fda-compounding-advisory-meeting-ll-37-ghk-cu-dihexa/Peptide Policy Watchen2026-10-30FDA's next peptide compounding meeting: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF https://peptidepolicywatch.com/2026/10/30/hhs-six-peptides-reasons-checked-against-research/Peptide Policy Watchen2026-10-30HHS's reasons for each of the six peptides, checked against the research https://peptidepolicywatch.com/2026/10/30/hhs-peptide-policy-federal-register-comment-period/Peptide Policy Watchen2026-10-30HHS's peptide policy is in the Federal Register: what the comment period does and doesn't decide https://peptidepolicywatch.com/2026/10/29/retatrutide-vs-ozempic-transcend-t2d-2-results-compounding/Peptide Policy Watchen2026-10-29Retatrutide vs. Ozempic: what the TRANSCEND-T2D-2 head-to-head found, and why it still can't be compounded https://peptidepolicywatch.com/2026/10/29/retatrutide-telehealth-offers-fda-lilly-enforcement/Peptide Policy Watchen2026-10-29Retatrutide: Telehealth companies are offering it. What do Lilly and the FDA have to say about it? https://peptidepolicywatch.com/2026/10/29/retatrutide-evidence-triumph-trials-fda-status/Peptide Policy Watchen2026-10-29Retatrutide explained: the TRIUMPH results, FDA status and why it can't be compounded https://peptidepolicywatch.com/2026/10/29/retatrutide-compounding-hhs-peptide-policy-what-changed/Peptide Policy Watchen2026-10-29Is retatrutide legal to compound now? What the HHS peptide policy actually says https://peptidepolicywatch.com/2026/10/29/peptides-recovery-and-sleep-claims-what-the-evidence-shows/Peptide Policy Watchen2026-10-29Peptides for recovery and sleep: what the human evidence actually shows https://peptidepolicywatch.com/2026/10/29/how-to-read-a-clinical-trial-listing/Peptide Policy Watchen2026-10-29How to read a clinical-trial listing on ClinicalTrials.gov: status, phase, dates and results https://peptidepolicywatch.com/2026/10/29/hhs-interim-peptide-compounding-policy-six-peptides/Peptide Policy Watchen2026-10-29HHS opens a compounding path for six peptides: what the interim policy says